How Analysts Feel About Viking Therapeutics, Inc. (VKTX) After Today’s Big Increase?

July 11, 2018 - By Lawrence Diaz

Viking Therapeutics, Inc. (NASDAQ:VKTX) Logo

The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) is a huge mover today! The stock increased 3.09% or $0.3 during the last trading session, reaching $10. About 1.71 million shares traded. Viking Therapeutics, Inc. (NASDAQ:VKTX) has risen 320.16% since July 11, 2017 and is uptrending. It has outperformed by 307.59% the S&P500.
The move comes after 9 months positive chart setup for the $595.58M company. It was reported on Jul, 11 by We have $10.40 PT which if reached, will make NASDAQ:VKTX worth $23.82M more.

Analysts await Viking Therapeutics, Inc. (NASDAQ:VKTX) to report earnings on August, 8. They expect $-0.11 EPS, up 47.62 % or $0.10 from last year’s $-0.21 per share. After $-0.10 actual EPS reported by Viking Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 10.00 % negative EPS growth.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Coverage

Among 5 analysts covering Viking Therapeutics (NASDAQ:VKTX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Viking Therapeutics had 6 analyst reports since March 8, 2018 according to SRatingsIntel. The rating was maintained by Maxim Group with “Buy” on Friday, June 1. H.C. Wainwright maintained it with “Buy” rating and $1500 target in Friday, June 1 report. The rating was reinitiated by H.C. Wainwright with “Buy” on Monday, March 26. The rating was maintained by Roth Capital on Thursday, March 8 with “Buy”.

More notable recent Viking Therapeutics, Inc. (NASDAQ:VKTX) news were published by: which released: “3 Growth Stocks at Deep-Value Prices” on June 15, 2018, also with their article: “3 Small-Cap Biotech Stocks to Keep on Your Radar” published on June 20, 2018, published: “Viking Therapeutics, Buy the Dip?” on June 26, 2018. More interesting news about Viking Therapeutics, Inc. (NASDAQ:VKTX) were released by: and their article: “3 Top Biotech Stocks to Buy for the 2nd Half of 2018” published on July 08, 2018 as well as‘s news article titled: “Viking Therapeutics: What Now After ‘Yuge’ Rally?” with publication date: June 12, 2018.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. The company has market cap of $595.58 million. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. It currently has negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.